-
STTT Wang Wei's team from Huazhong University of Science and Technology proved that CAR-T cell
Time of Update: 2023-02-03
Original link: style="margin-right: auto;margin-left: auto;outline: 0px;width: 30px;display: inline-block;">—END—The content is [iNature]iNatureNeuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disease of the central nervous system (CNS) with a recurrent course and severe sequelae 。 The discovery of anti-aquaporin 4 (AQP4) autoantibodies has led to an understanding of its pathophysiology and precise targeting of plasma cells producing immunoglobulin G (IgG) that binds to AQP4 on the optic nerve and spinal cord, leading to a variety of pathological outcomes.
-
JCO(IF=51) Shanghai Jiao Tong University multi-unit cooperation, Academician Pei Zhengkang's team
Time of Update: 2023-01-06
iNatureIt is unclear whether combination therapy with CD19 and CD22 chimeric antigen receptor T cells leads to durable event-free survival in children with refractory disease or high-risk B acute lymp
-
JCO(IF=51) Shanghai Jiao Tong University multi-unit cooperation, Academician Pei Zhengkang's team
Time of Update: 2023-01-06
iNatureIt is unclear whether combination therapy with CD19 and CD22 chimeric antigen receptor T cells leads to durable event-free survival in children with refractory disease or high-risk B acute lymp
-
The University of Glasgow in the United Kingdom develops a new battery to charge an electric car in seconds
Time of Update: 2022-11-26
Since this technology allows electric vehicles to be charged in seconds, which is no different from the refueling time of conventional vehicles, this innovative technology is expected to solve the current energy supply problem.
-
Tokyo University of Science optimizes the weight of carbon fiber composites to help make lighter cars
Time of Update: 2022-11-17
According to foreign media reports, recently, researchers at Tokyo University of Science (Tokyo University of Science) recently adopted a new design method that can optimize the thickness and orientation of fibers at the same time, thereby reducing the weight of reinforced plastics and helping to develop lighter aircraft and car .
-
Tokyo University of Science optimizes the weight of carbon fiber composites to help make lighter cars
Time of Update: 2022-11-17
According to foreign media reports, recently, researchers at Tokyo University of Science (Tokyo University of Science) recently adopted a new design method that can optimize the thickness and orientation of fibers at the same time, thereby reducing the weight of reinforced plastics and helping to develop lighter aircraft and car .
-
Kong Delin, Hu Yongxian, Zhejiang University, et al.: It is safe and effective for patients
Time of Update: 2022-11-15
Journal of Zhejiang University (English Edition) Series B: Biomedicine and Biotechnology,JZUS-B receives articles in life sciences, medicine, pharmacy, biochemistry, biotechnology and bioengineering, agronomy, ecology, and zoology.
-
Gu Tianning, Hu Yongxian, Zhejiang University, et al.: B-cell malignant tumors recur after CAR-T cell therapy: challenges and future
Time of Update: 2022-11-05
Content introductionChinese Summary:Outline:As a new type of cellular immunotherapy, chimeric antigen receptor T (CAR-T) cell therapy has greatly changed the landscape of cancer treatment, especially in hematologic malignancies.
-
Science Translational Medicine: CRISPR gene-edited universal CAR-T, clinical trial results for the treatment of childhood leukemia released
Time of Update: 2022-11-04
The research team used next-generation CRISPR-Cas9 gene editing technology to knock out TRAC and CD52 of CAR19 T cells, construct a universal CAR-T cell, TT52CAR19 T cells, and conducted a phase 1 clinical trial for the treatment of childhood B-cell acute lymphoblastic leukemia (B-ALL).
-
STM: CRISPR gene-edited universal CAR-T, clinical trial results for the treatment of childhood leukemia released
Time of Update: 2022-11-04
The research team used next-generation CRISPR-Cas9 gene editing technology to knock out TRAC and CD52 of CAR19 T cells, construct a universal CAR-T cell, TT52CAR19 T cells, and conducted a phase 1 clinical trial for the treatment of childhood B-cell acute lymphoblastic leukemia (B-ALL).
-
JCO: Chen Saijuan's team at Shanghai Jiao Tong University found the newly developed CAR-T method effective in treating relapsed/refractory multiple myeloma
Time of Update: 2022-10-31
00690 On October 21, 2022, 11 companies including Shanghai Jiao Tong University, Xi'an Jiaotong University, and Peking University joined forces, and Chen Saijuan was the corresponding author in the Journal of Clinical Oncology (IF=51) published online titled “Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor–T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)", this pivotal Phase II open-label study (ClinicalTrials.
-
Allogene: Developed universal CAR-T with the help of oncologists across the United States
Time of Update: 2022-10-20
544px;background-color: rgb(255, 255, 255);text-align: center;box-sizing: border-box !important;overflow-wrap: break-word !important;margin-bottom: 0px;">——List of recent popular events——▼October 13, Sino-US Double Report Cell Bank Verification Strategy Seminar▼October 14,—— ▼October 18, the application and development trend of biopharmaceutical safety detection technologyOctober 13, 2022 /eMedClub News/-CAR-T therapy is a breakthrough treatment that has been a boon to many oncology patients, but its pricing and preparation process have significantly limited accessibility.
-
Can Universal CAR-T Cross Brain Tumor "No Man's Land" DJS
Time of Update: 2022-09-06
Click on the image for the DJSeedin agendaWritten by Cheng LongIn the field of cell therapy, universal CAR-T (UCAR-T) has shown broader therapeutic prospects, but the allogeneic rejection limits the application of UCAR-T in the field of tumors, especially solid tumors .
-
Shanghai Jiaotong University Yang Xuanming's team discovered a new target for CAR-T treatment of T-cell malignant tumors
Time of Update: 2022-08-20
Recently, the internationally important academic journal "Nature Communications" published online the research results "T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies" by Yang Xuanming's team from Sheng Yushou Cell and Immunology Research Center of Shanghai Jiao Tong University .
-
Universal CD20 CAR-γδ T cell therapy has been granted Fast Track designation by the US FDA. What are the advantages of γδ T cells?
Time of Update: 2022-06-12
▲ Adicet’s γδ T cell-based cell therapy process (Image source: Adicet’s official website) In addition, Adicet has demonstrated that it can target by generating and validating high-affinity and high-specificity T cell receptor-like monoclonal antibodies (TCRLs) The intracellular proteome, these TCRLs against disease-specific antigens presented on the cell surface by MHC class I complexes, could be exploited to arm γδ T cells, as T cell linkers, and as ADCs .